System for enhanced detection of atrial fibrillation

By using the ventricular septum and RSA detector in the atrial fibrillation (AF) detection, the RSA-related false positives are eliminated, and the problem of high false positive error rate of AF detection in the prior art is solved, and the detection accuracy is improved.

CN113301849BActive Publication Date: 2024-11-15CARDIAC PACEMAKERS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080008285.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-01-09
Filing Date
2020-01-08
Publication Date
2024-11-15
Estimated Expiration
2040-01-08

AI Technical Summary

Technical Problem

The prior art has a higher false positive error rate due to respiratory sinus arrhythmia (RSA) in detecting atrial fibrillation (AF), which increases the workload of doctors and clinics.

Method used

By using the ventricular septum to detect AF, combined with the RSA detector, false positive detection is eliminated by detecting RSA, reducing AF detection errors associated with RSA.

Benefits of technology

It effectively reduces the false positive error rate in AF test, improves the accuracy of the test, and reduces unnecessary medical response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113301849B_ABST
    Figure CN113301849B_ABST
Patent Text Reader

Abstract

An example of a system may include a sensing circuit and an atrial fibrillation (AF) detection circuit. The sensing circuit may be configured to sense a cardiac signal indicative of atrial and ventricular depolarization. The AF detection circuit may be configured to detect atrial fibrillation using the cardiac signal, and may include a detector and a detection enhancer. The detector may be configured to detect ventricular depolarization using the cardiac signal, to measure the ventricular interval between two consecutive detected ventricular depolarizations, and to detect AF using the ventricular interval. The detection enhancer may include a respiratory sinus arrhythmia (RSA) detector configured to detect RSA using the cardiac signal, and may be configured to verify each detection of AF based on whether RSA is detected.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority claim

[0002] This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Serial No. 62 / 790,215, filed on January 9, 2019, which is incorporated herein by reference in its entirety. Technical Field

[0003] This document relates generally to cardiac rhythm management and, more particularly, to methods and apparatus for enhancing atrial fibrillation (AF) detection by reducing false positive errors associated with respiratory sinus arrhythmia (RSA). Background Art

[0004] The heart is the center of an individual's circulatory system. The left side of the heart, including the left atrium (LA) and the left ventricle (LV), draws oxygenated blood from the lungs and pumps it to the body's organs, thereby providing the organs with their metabolic needs for oxygen. The right side of the heart, including the right atrium (RA) and the right ventricle (RV), draws deoxygenated blood from the body's organs and pumps it to the lungs, where the blood is oxygenated. These mechanical pumping functions are accomplished by the contraction of the heart. In a normal heart, the sinoatrial (SA) node (the heart's natural pacemaker) generates electrical impulses called action potentials, which are propagated through the conductive system to various areas of the heart, causing the muscle tissue in those areas to depolarize and contract in a normal sinus rhythm.

[0005] When the heart contracts at a rate higher than the normal sinus rhythm, a tachyarrhythmia occurs. Tachyarrhythmias generally include ventricular tachyarrhythmias (VT) and supraventricular tachyarrhythmias (SVT). For example, VT occurs when a pathological conduction circuit is formed in the ventricles (through which electrical impulses circulate in the ventricles) or when a pathologically formed electrical focus generates electrical impulses from the ventricles. SVT can be physiological (such as sinus tachycardia) or pathological (such as atrial fibrillation). Physiological sinus tachycardia occurs when the SA node generates electrical impulses at a particularly high rate. For example, when a pathological conduction circuit is formed in the atrium or both atria, pathological SVT occurs. Fibrillation occurs when the heart contracts at a tachyarrhythmia rate with an irregular rhythm. Ventricular fibrillation (VF), as a ventricular arrhythmia with irregular conduction, is a life-threatening condition that requires immediate medical treatment, such as ventricular defibrillation. Atrial fibrillation (AF), as a SVT with an irregular rhythm, although not directly life-threatening, also requires medical attention for purposes such as assessing the patient's cardiovascular status, atrial defibrillation, and / or adjusting other treatments received by the patient to restore cardiovascular function and / or prevent deterioration of the heart. Summary of the invention

[0006] An example of a system (e.g., "Example 1") may include a sensing circuit and an atrial fibrillation (AF) detection circuit. The sensing circuit may be configured to sense a cardiac signal indicative of atrial and ventricular depolarization. The AF detection circuit may be configured to detect AF using the cardiac signal, and may include a detector and a detection enhancer. The detector may be configured to detect ventricular depolarization using the cardiac signal, measure a ventricular interval between two consecutive detected ventricular depolarizations, and detect AF using the ventricular interval. The detection enhancer may include a respiratory sinus arrhythmia (RSA) detector configured to detect RSA using the cardiac signal, and may be configured to verify each detection of AF based on whether RSA is detected.

[0007] In Example 2, the subject matter of Example 1 can optionally be configured such that the detector is configured to calculate a measure of ventricular rate variability using the ventricular interval and to indicate a suggested detection of AF in response to the measure of ventricular rate variability satisfying one or more criteria for AF, and the detection enhancer is configured to indicate detection of AF in response to indicating the suggested detection of AF while RSA is not detected.

[0008] In Example 3, the subject matter of any one or any combination of Examples 1 and 2 may optionally be configured such that the detection booster is configured to negate detection of AF when RSA is detected.

[0009] In Example 4, the subject matter of any one or any combination of Examples 1 to 3 may optionally be configured such that the detection enhancer is configured to indicate a false positive detection of AF when AF is detected by the detector while RSA is detected.

[0010] In Example 5, the subject matter of any one or any combination of Examples 1 to 4 can optionally be configured such that the RSA detector includes a run detector and a run analyzer. The run detector is configured to detect runs with consecutive faster heartbeats and consecutive slower heartbeats based on the heart signal within a time period. The run analyzer is configured to analyze the detected runs for an RSA pattern and declare detection of RSA in response to the presence of the RSA pattern.

[0011] In Example 6, the subject matter of Example 5 can optionally be configured such that the run analyzer is configured to generate a histogram of the percentage of each run having a number of heartbeats plotted relative to the duration of the run specified by the number of heartbeats.

[0012] In Example 7, the subject matter of Example 6 can optionally be configured such that the run analyzer is configured to detect an RSA profile that includes at least one of a significantly low percentage of 1-beat runs or an increasing number of multi-beat runs as the number of beats in each of the multi-beat runs increases.

[0013] In Example 8, the subject matter of any one or any combination of Examples 1 to 7 can optionally be configured to include an implantable medical device comprising the sensing circuit and the AF detection circuit.

[0014] In Example 9, the subject matter of Example 8 can optionally be configured such that the sensing circuit is configured to sense a ventricular electrogram.

[0015] In Example 10, the subject matter of Example 8 can optionally be configured such that the sensing circuit is configured to sense a subcutaneous electrocardiogram.

[0016] In Example 11, the subject matter of Example 8 can optionally be configured such that the implantable medical device includes an implantable loop recorder.

[0017] In Example 12, the subject matter of any one or any combination of Examples 1 to 11 can optionally be configured to further include a treatment device and a treatment control circuit. The treatment device is configured to deliver one or more treatments. The treatment control circuit is configured to control the delivery of one or more treatments based on whether each detection of AF is verified.

[0018] In Example 13, the subject matter of Example 12 can optionally be configured such that the implantable medical device comprises a subcutaneous implantable cardioverter-defibrillator.

[0019] In Example 14, the subject matter of Example 12 can optionally be configured such that the implantable medical device includes a ventricular implantable cardioverter-defibrillator.

[0020] In Example 15, the subject matter of any one or any combination of Examples 1 to 14 can optionally be configured to further include a storage device and a storage control circuit. The storage device is configured to store the portions of the sensed cardiac signal. The storage control circuit is configured to begin storing a portion of the portions of the sensed cardiac signal in response to each detection of AF being verified.

[0021] An example of a method is also provided (e.g., "Example 16"). The method may include: sensing a cardiac signal indicative of atrial and ventricular depolarization; detecting ventricular depolarization using the cardiac signal; measuring a ventricular interval between two consecutive detected ventricular depolarizations; detecting atrial fibrillation (AF) using the ventricular interval; detecting respiratory sinus arrhythmia (RSA) using the cardiac signal; and validating each detection of AF based on whether RSA is detected.

[0022] In Example 17, the subject matter of detecting AF using the ventricular septum as found in Example 16 may optionally include calculating a measure of ventricular rate variability using the ventricular septum, and indicating a proposed detection of AF in response to the measure of ventricular rate variability satisfying one or more criteria for AF, and the subject matter of verifying each detection of AF as found in Example 16 may optionally include indicating a detection of AF in response to indicating a proposed detection of AF while no RSA is detected.

[0023] In Example 18, the subject matter of any one or any combination of Examples 16 and 17 may optionally further include negating detection of AF when RSA is detected.

[0024] In Example 19, the subject matter of any one or any combination of Examples 16 to 18 may optionally further include indicating a false positive detection of AF when AF is detected while RSA is detected.

[0025] In Example 20, the subject matter of any one or any combination of Examples 16 to 19 may optionally further include triggering storage of the sensed cardiac signal in response to each detection of AF being verified.

[0026] In Example 21, the subject matter of detecting RSA as found in any one or any combination of Examples 16 and 17 may optionally also include: detecting runs having consecutive faster heartbeats and consecutive slower heartbeats based on a cardiac signal within a time period; analyzing the detected runs for an RSA spectrum; and declaring detection of RSA in response to the presence of an RSA spectrum.

[0027] In Example 22, the subject matter of analyzing the detected runs for RSA profiles as discovered in Example 21 can optionally include generating a histogram of the percentage of each run having a number of heartbeats plotted relative to the duration of the run specified by the number of heartbeats, and detecting an RSA profile that includes at least one of a significantly low percentage of 1-beat runs or an increasing number of multi-beat runs as the number of beats in each of the multi-beat runs increases.

[0028] In Example 23, the subject matter of sensing a cardiac signal as found in any one or any combination of Examples 16 to 22 may optionally include sensing a subcutaneous electrocardiogram from a site remote from the heart.

[0029] In Example 24, the subject matter of any one or any combination of Examples 16 to 23 may optionally further include delivering one or more therapies, and controlling the delivery of the one or more therapies based on whether each detection of AF is verified.

[0030] In Example 25, the subject matter of delivering one or more therapies as found in any one or any combination of Example 24 can optionally include delivering at least one of the one or more therapies from an implantable medical device.

[0031] This summary is an overview of some of the teachings of the present application and is not intended to be an exclusive or exhaustive treatment of the subject matter. More details about this subject matter can be found in the detailed description and the appended claims. Other aspects of the present disclosure will be apparent to those skilled in the art upon reading and understanding the following detailed description and viewing the accompanying drawings that form a part thereof (each of which is not viewed in a limiting sense). The scope of the present disclosure is limited by the appended claims and their legal equivalents. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The accompanying drawings generally illustrate various embodiments discussed in this document by way of example. The drawings are for illustration purposes only and may not be drawn to scale.

[0033] Figure 1 is a block diagram illustrating an embodiment of an atrial fibrillation (AF) detection circuit.

[0034] Figure 2 is a flow chart illustrating an embodiment of a method for detecting AF.

[0035] Figure 3 is a diagram showing a respiratory sinus arrhythmia (RSA) detector that can be used to enhance AF detection (e.g., in Figure 1 A block diagram of an embodiment of an AF detection circuit).

[0036] Figure 4 is a diagram showing that the method for detecting AF (such as Figure 2 Flow chart of an embodiment of a method for detecting RSA used in a method of detecting RSA.

[0037] Figure 5A is a graph showing an example of heart rate variation with breathing.

[0038] Figures 5B to 5G It is shown in the use Figure 4 Histograms of various examples of run-length distributions in RSA detection using the method.

[0039] Figure 6 It is shown that Figure 1 A block diagram of an embodiment of an AF detection circuit for a medical device.

[0040] Figure 7 is a diagram of an embodiment of a cardiac rhythm management (CRM) system and portions of an environment in which the system operates.

[0041] Figure 8 is a diagram of another embodiment of a cardiac rhythm management system and portions of an environment in which the system operates.

[0042] Fig. 9 It is shown that Figure 1 A block diagram of an embodiment of a CRM detection circuit of an AF detection circuit. DETAILED DESCRIPTION

[0043] In the following detailed description, reference is made to the accompanying drawings, which form a part of the present invention and in which are shown by way of illustration specific embodiments in which the present invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that these embodiments may be combined, or other embodiments may be utilized, and structural, logical, and electrical changes may be made without departing from the spirit and scope of the present invention. The following detailed description provides examples, and the scope of the present invention is defined by the appended claims and their legal equivalents.

[0044] It should be noted that references to "an," "one," or "various" embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment.

[0045] This document discusses methods and systems for detecting atrial fibrillation (AF, also referred to as "AFib"). Existing methods for detecting AF include algorithms based on ventricular rate variability (or ventricular cycle length variability, also referred to as RR variability or VV variability), which is a measure of the beat-to-beat variance in the ventricular interval (the time interval between two consecutive ventricular depolarizations or R waves). However, this approach sometimes gives false-positive errors due to changes in the ventricular rate rather than due to changes in the atrial rate. In the case of devices that do not have electrical access to the right atrium (such as insertable cardiac monitors and ventricular defibrillators), atrial activity may not be directly detectable for enhanced AF detection. False-positive AF detections may occur due to naturally occurring phenomena that result in unstable ventricular heart rates. Examples of such phenomena include premature atrial contraction (PAC), premature ventricular contraction (PVC), Wenckebach phenomenon (second degree atrioventricular block, Mobitz I), and respiratory sinus arrhythmia (RSA). False positive AF detection by the device increases the workload of physicians and clinic staff in responding to and reviewing the resulting alarms.

[0046] The present system detects AF using the ventricular interval and excludes false positive detections by detecting RSA. RSA is heart rate variability that is synchronized with respiration, with which the ventricular cycle length (also called the RR interval or VV interval) on the electrocardiogram (ECG) shortens during inspiration and lengthens during exhalation. By detecting RSA and preventing the device from declaring an AF detection when RSA is being detected, the present system reduces false positive AF detections associated with RSA. In various embodiments, RSA may be detected alone or in combination with detection of one or more other phenomena to reduce the false positive error rate in AF detection. In various embodiments, a programmable option is provided to selected patients that enables automatic identification of AF using RSA.

[0047] RSA can also be indicated by periodic amplitude changes in the ECG signal. This allows the use of a single ECG signal to detect both AF and RSA. Depending on the need and application, the detection can be performed by a device implanted in the patient or otherwise worn by the patient and / or a remote server in communication with the device. In various embodiments, a statistical runs test can determine whether the ventricular cycle length (VV interval) changes in a particular data set are from a random process or a non-random periodic process (such as RSA).

[0048] In various embodiments, AF detection is performed for diagnostic and / or therapeutic purposes. In an embodiment, verified AF detection can trigger storage of cardiac signals for monitoring and diagnosing arrhythmic conditions in a patient, and the storage can continue until AF is no longer detected or verified. In another embodiment, in response to verified AF detection, therapy delivery to the patient can be started, stopped, or adjusted. Although some specific devices are discussed as examples in this document, the present systems and methods can be used with any device and system in which AF is to be detected.

[0049] As used herein, the relationship between heart rate and cardiac interval (also referred to as cardiac cycle length) is the relationship between frequency and its corresponding period. If the heart rate is given in units of beats per minute (bpm), its corresponding cardiac interval (in milliseconds) is calculated by dividing 60,000 by the heart rate (where 60,000 is the number of milliseconds in a minute). Any process using heart rate (such as comparison) should be modified accordingly when cardiac interval is used alternatively. Examples of heart rate include atrial rate and ventricular rate. Examples of cardiac interval (or cycle length) include atrial interval (or cycle length) and ventricular interval (or cycle length).

[0050] In this document, "user" includes a physician or other caregiver who examines and / or treats a patient using one or more of the methods and devices reported in this document.

[0051] Figure 1 is a block diagram illustrating an embodiment of an AF detection circuit 100. The AF detection circuit 100 may include a cardiac signal input 102, a detector 104, and a detection enhancer 108. The AF detection circuit 100 may detect AF using cardiac signals indicative of atrial and ventricular depolarization.

[0052] The cardiac signal input 102 receives cardiac signals indicative of atrial and ventricular depolarization. In various embodiments, the cardiac signal may include a single signal indicative of both atrial and ventricular depolarization, or multiple signals each indicative of at least one of atrial depolarization and ventricular depolarization.

[0053] The detector 104 can be configured to detect ventricular depolarizations (R waves) using the cardiac signal, to measure a ventricular interval (RR interval) each between two consecutive detected ventricular depolarizations, and to detect AF using the ventricular interval. In one embodiment, the detector 104 uses the ventricular interval to calculate a measure of ventricular rate variability, and indicates a suggested detection of AF in response to the measure of ventricular rate variability satisfying one or more criteria for AF. Ventricular rate variability (or ventricular cycle length variability, also referred to as RR variability or VV variability) corresponds to heart rate variability (HRV) measured over a relatively short period of time. In one embodiment, the detector 104 measures a ventricular interval each associated with the detected ventricular depolarization, and determines the ventricular rate variability as the beat-to-beat variance of the ventricular interval over a specific number of heartbeats or a specific time interval. Examples of AF detection using ventricular rate variability are discussed in U.S. patent application publication No. US2016 / 0045125A1, entitled “ATRIAL FIBRILLATION DETECTION USING VENTRICULAR RATE VARIABILITY,” and U.S. Patent No. 9,999,368, entitled “ATRIAL FIBRILLATION DETECTION,” both assigned to Cardiac Pacemakers, Inc., the entire contents of which are incorporated herein by reference.

[0054] Heart rate is rhythmic and varies with breathing. Using heart rate variability / stability measurements, the heart rate may appear very unstable and, therefore, may lead to false positive detections of AF. The present subject matter can reduce such false positive detections of AF associated with RSA. The detection enhancer 108 may include an RSA detector 108 that detects RSA using cardiac signals, and can verify the detection of AF based on whether RSA is detected. When RSA is detected while RSA is not detected, verify the detection of AF, such as a suggested detection of AF. The detection enhancer 108 may indicate the detection of AF in response to indicating a suggested detection of AF while RSA is not detected. When RSA is detected, the detection enhancer 108 may mark the detection of AF as a false positive detection and / or negate the detection of AF.

[0055] Figure 2 2 is a flow chart illustrating an embodiment of a method 210 for detecting AF. In one embodiment, the AF detection circuit 100 is configured to perform the method 210. For example, the detector 104 may be configured to perform steps 212 to 214, and the detection enhancer 108 may be configured to perform steps 215 and 216.

[0056] At 211, a cardiac signal is sensed. At 212, ventricular depolarization is detected from the sensed cardiac signal. At 213, a ventricular interval is measured. At 214, AF is detected using the ventricular interval. In various embodiments, a parameter representing ventricular rate variability is calculated using the ventricular interval, and AF is detected based on this parameter. A suggested detection of AF can be indicated in response to the detection of AF based on the parameter.

[0057] At 215, RSA is detected using the sensed cardiac signal. At 216, each detection of AF is verified based on whether RSA is detected. Detection of AF is indicated in response to indicating a suggested detection of AF while RSA is not detected. When a suggested detection of AF is indicated while RSA is detected, the detection of AF is negated and / or a false positive detection of AF is indicated. In various embodiments, in response to the detection of AF being verified, storage of data representing the detection of AF and a portion of the cardiac signal associated with the detected AF is triggered.

[0058] Figure 3 is a block diagram illustrating an embodiment of an RSA detector 308 that can be used to enhance AF detection. The RSA detector 308 can represent an example of the RSA 108, and can include a runs detector 320 and a runs analyzer 322. Although the detection of RSA using a statistical runs test is discussed as an example, the detection of RSA for verifying the detection of AF according to the present subject matter is not limited to the use of a statistical runs test, but any method suitable for detecting RSA can be used.

[0059] The statistical runs test determines whether a data set represents a random process. A run is a series of increasing values ​​or a series of decreasing values ​​within a data set. The number of increasing values ​​or decreasing values ​​is the duration of the run. The basis for the runs test is that in a random data set, the probability of the next value being larger or smaller follows a binomial distribution. In the NIST / SEMATECH e-Handbook of Statistical Methods, https: / / www.itl.nist.gov / div898 / handbook / eda / section3 / eda35d.htm , 2013. The statistical run test is discussed in RSA detector 308, which includes run detector 320 and run analyzer 322, can be configured to detect RSA using such a run test.

[0060] The run detector 320 can detect runs of consecutive faster beats and consecutive slower beats within a time period. A consecutive faster beat is a consecutive heartbeat with an increased cardiac cycle length. A consecutive slower beat is a consecutive heartbeat with a reduced cardiac cycle length. In various embodiments, the time period can be specified between 30 seconds and 24 hours, with 2 minutes, 6 minutes, and 10 minutes being specific examples.

[0061] The run analyzer 322 can analyze the detected runs for RSA profiles and declare the detection of RSA in response to the presence of the RSA profile. The RSA profile includes a non-random periodic profile of ventricular rate or cycle length. When the run analyzer 322 determines that there is a non-random, periodic profile of ventricular rate or cycle length, RSA is detected. In various embodiments, the run analyzer 322 can detect the RSA profile from a run percentage histogram plotted relative to the run duration (number of beats per run). The RSA profile is characterized by a lower percentage of 1-beat runs and / or a significantly increased number of longer runs. In various embodiments, the run analyzer 322 can detect the RSA profile when the percentage of 1-beat runs is below a specified threshold percentage and / or an increasing trend exists in the number of multi-beat runs as the number of beats in one or more of the multi-beat runs increases. The increasing trend exists when the number of multi-beat runs increases significantly as the number of beats in one or more of the multi-beat runs increases. The threshold percentage for 1-beat runs can be specified between 1% and 50%, with 30%, 35%, and 40% being specific examples. An "increasing trend" or "significant increase" means that as the number of beats in each of the multi-beat runs increases (e.g., from a 3-beat run to a 4-beat run), the number (or percentage) of runs increases or remains constant (e.g., 5 3-beat runs and 10 or more 4-beat runs). The number can be specified between 1 and 1000, with 0, 5, and 10 being specific examples, or the absolute percentage can be specified between 0% and 99%, with 5%, 10%, and 20% being specific examples. The percentage can also be specified as a relative percentage increase (e.g., 25% more 4-beat runs than 3-beat runs).

[0062] Figure 4 4 is a flow chart illustrating an embodiment of a method 430 for detecting RSA, which represents an example, but not a limitation, of how step 215 of method 210 may be performed. In one embodiment, RSA detector 308 is configured to perform method 430. For example, run length detector 320 may be configured to perform step 431, and run length analyzer 322 may be configured to perform steps 432 and 433.

[0063] At 431, a run having consecutive faster heartbeats and consecutive slower heartbeats is detected from the heart signal within the time period. At 432, the detected run is analyzed to obtain an RSA spectrum. At 433, in response to the existence of the RSA spectrum, detection of RSA is declared. Figure 5Ais a graph showing an example of RSA where the ventricular rate is rhythmic and varies with respiration. In various embodiments, the RSA pattern can be detected from a histogram of run percentages plotted against run duration (number of beats per run). The RSA pattern can be detected by detecting a non-random periodic pattern of ventricular rate as indicated by the histogram. For example, the RSA pattern can be detected in response to the percentage of 1-beat runs being below a specified percentage or the presence of an increasing number of multi-beat runs as the number of beats in each of the multi-beat runs increases. Examples of such histograms are shown in FIG. FIG. 5B to FIG. 5F Shown in.

[0064] FIG. 5B to FIG. 5F 4 is a histogram showing various examples of run-length distribution in RSA detection using method 430 . Figure 5B , Figure 5C and Figure 5D An example of run length distribution when RSA is present during normal sinus rhythm is shown. Figure 5E , Fig. 5F and Figure 5G An example of a run distribution with no indication of RSA during AF is shown. Note that depending on the patient and circumstances, RSA may not always be detectable using a statistical runs test, but when it is detected it can be used to negate a false detection of AF.

[0065] In various embodiments, the RSA detector 108 may include only the RSA detector 308, one or more different RSA detectors that each use a different method to detect RSA, or a combination of the RSA detector 308 and one or more different RSA detectors. Step 215 of method 210 may be performed using only the method 430, one or more different methods for detecting RSA, or a combination of the method 430 and one or more different methods. In various embodiments, ventricular rate variability and / or any other method may be used to detect AF. Verification of detection of AF based on the presence or absence of RSA is independent of the specific method used to detect AF.

[0066] Figure 6 is a block diagram illustrating an embodiment of a medical device 640 that includes the AF detection circuit 100. While examples of medical device 640 include an implantable loop recorder (ILR) that senses one or more ventricular signals, a single chamber ICD in which atrial electrograms are not sensed, a diagnostic patch or wearable device that senses a surface ECG, and a subcutaneous device that is implanted subcutaneously to sense cardiac activity, medical device 640 represents any medical device that detects AF using detection and RSA-based authentication as discussed herein.

[0067] In various embodiments, the circuits of the medical device 640 (including the AF detection circuit 100) can be implemented using a combination of hardware and software. In various embodiments, each element of the AF detection circuit 100 (including its various embodiments) can be implemented using a dedicated circuit configured to perform one or more specific functions or a general-purpose circuit programmed to perform (multiple) such functions. For example, the detector 104 and the detection enhancer 106 (including the RSA detector 108) can each be implemented using a dedicated circuit configured to perform one or more functions discussed as (multiple) methods or (multiple) method steps in this document or a general-purpose circuit programmed to perform (multiple) such functions. Such general-purpose circuits include, but are not limited to, a microprocessor or a portion thereof, a microcontroller or a portion thereof, and a programmable logic circuit or a portion thereof.

[0068] Figure 7 750 and an external system 752. The system 760 includes an implantable system 750, an external system 752, and a telemetry link 754 that provides communication between the implantable system 750 and the external system 752.

[0069] The implantable system 750 includes, among other things, an implantable medical device 740 and a lead system 758. In various embodiments, the implantable medical device 740 is an implantable CRM device, including one or more of a cardiac monitor, a pacemaker, a cardioverter / defibrillator, a cardiac resynchronization therapy (CRT) device, a cardiac remodeling control therapy (RCT) device, a neurostimulator, a drug delivery device or drug delivery controller, and a biotherapeutic device. Figure 7 As shown, the implantable medical device 740 is implanted in the patient's body 799. In various embodiments, the lead system 758 includes leads for sensing physiological signals and delivering pacing pulses, cardioversion / defibrillation shocks, neural stimulation pulses, medicaments, biological agents, and / or other types of energy or substances for treating cardiac conditions. In one embodiment, the lead system 758 includes one or more pacing sensing leads each including at least one electrode placed in or on the patient's heart 798 for sensing electrograms and / or delivering pacing pulses. In other embodiments, electrodes placed in the body 799 but away from the heart 798 are used to sense physiological signals and deliver pacing pulses, cardioversion / defibrillation shocks, neural stimulation pulses, medicaments, biological agents, and / or other types of energy or substances for treating cardiac conditions. In a specific embodiment, one or more electrodes are incorporated into the implantable medical device 740 for subcutaneous placement.

[0070] The implantable medical device 740 includes an AF detection circuit 100 for detecting AF. In various embodiments, the implantable medical device 740 adjusts the delivery of pacing pulses, cardioversion / defibrillation shocks, neural stimulation pulses, drugs, biologics, and / or other types of energy or substances for treating cardiac conditions in response to each detection of AF. For example, the implantable medical device 740 can be configured to deliver CRT or another therapy for treating heart failure, determine the AF load as the percentage of time during which AF is indicated, and adjust the CRT and / or other therapy based on the AF load. The other therapy can be delivered by the implantable medical device 740 or using another device associated with or independent of the implantable medical device 740.

[0071] In various embodiments, the AF detection circuit 100 provides the implantable medical device 740 with the ability to detect AF. This eliminates the need to access the atria for atrial tachyarrhythmia detection when access to the atria is not otherwise required.

[0072] The external system 752 allows the user and / or patient to control the operation of the implantable medical device 740 and obtain information acquired by the implantable medical device 740. In one embodiment, the external system 752 includes a programmer that communicates bidirectionally with the implantable medical device 740 via a telemetry link 754. In another embodiment, the external system 752 is a patient management system that includes an external device that communicates with a remote device through a telecommunications network. The external device is near the implantable medical device 740 and communicates bidirectionally with the implantable medical device 740 via a telemetry link 754. The remote device allows the user to monitor and treat the patient from a remote location.

[0073] The telemetry link 754 provides for the transmission of data from the implantable medical device 740 to the external system 752. This includes, for example, the transmission of real-time physiological data acquired by the implantable medical device 740, the extraction of physiological data acquired by and stored in the implantable medical device 740, the extraction of treatment history data stored in the implantable medical device 740, and the extraction of data indicating the operating state (e.g., battery state and lead impedance) of the implantable medical device 740. The telemetry link 754 also provides for the transmission of data from the external system 752 to the implantable medical device 740. This includes, for example, programming the implantable medical device 740 to acquire physiological data, programming the implantable medical device 740 to perform at least one self-diagnostic test (such as for the device operating state), and programming the implantable medical device 740 to deliver at least one therapy.

[0074] Figure 8is an illustration of an embodiment of a CRM system 860 and a portion of the environment in which the system 860 operates. The system 860 includes an implantable system 850, an external system 752, and a telemetry link 754 that provides communication between the implantable system 850 and the external system 752. The implantable system 850 differs from the implantable system 750 in that it includes an implantable medical device 840 without a lead system. The implantable medical device 840 is a cardiac monitoring device that includes an AF detection circuit 100 for the ability to detect AF without leads for providing an electrical connection to the heart 798. In various embodiments, the implantable medical device 840 detects atrial arrhythmias and communicates an indication of one or more specific types of atrial arrhythmias to the external system 752 via the telemetry link 754 on a continuous or periodic basis or upon request. Such an indication provides a physician or other caregiver with information necessary to treat a patient. For example, the implantable medical device 840 can be configured to detect AF in a patient with heart failure. Implantable medical device 840 or external system 752 may be configured to determine AF burden and then use it as a basis for initiating, stopping, or adjusting one or more therapies for treating heart failure.

[0075] Fig. 9 is a block diagram illustrating an embodiment of a CRM circuit 970 including the AF detection circuit 100. The CRM circuit 970 may be an example of a circuit in an implantable medical device 640, 740, or 840, and may be configured for use in any medical device that provides for CRM and detects AF. The CRM circuit 970 may include a sensing circuit 972, a treatment device 974, a control circuit 976, and a storage device 978.

[0076] Sensing circuit 972 senses one or more cardiac signals indicative of atrial depolarization (P wave) and ventricular depolarization (R wave). Examples of such one or more cardiac signals include one or more electrocardiograms (ECGs), one or more subcutaneous ECGs, and one or more intracardiac electrograms (such as atrial and ventricular electrograms). Each of these signals can be an example of a cardiac signal from which AF and RSA can be detected, as discussed herein.

[0077] Therapeutic device 974 delivers one or more therapies. Examples of such one or more therapies include cardiac pacing circuits that deliver cardiac pacing pulses, cardioversion / defibrillation circuits that deliver cardioversion / defibrillation shocks, neural stimulation circuits that deliver neural stimulation pulses or other forms of neural stimulation energy, drug delivery devices that deliver one or more drugs, and biological therapeutic devices that deliver one or more biological therapies. In various embodiments, the one or more therapies are each used to treat AF and / or are adjusted as necessary or preferred based on whether AF is detected.

[0078] The storage device 978 stores portions of the sensed one or more cardiac signals. In various embodiments, the storage device 978 also stores various control algorithms used by the control circuit 976 and other signals acquired by the CRM circuit 970. In various embodiments, only data associated with verified AF detection is stored.

[0079] The control circuit 976 controls the operation of the CRM circuit 970 and may include an arrhythmia detection circuit 980, a therapy control circuit 982, and a storage control circuit 984. The arrhythmia detection circuit 980 uses one or more cardiac signals to detect one or more types of arrhythmias and includes an AF detection circuit 100 that uses at least one of the one or more cardiac signals to detect AF. The therapy control circuit 982 controls the delivery of one or more therapies from the therapy device 974 using the one or more cardiac signals. In various embodiments, the therapy control circuit 982 starts, stops, or adjusts the delivery of the therapy in the one or more therapies in response to the detection of one of the one or more types of arrhythmias. In various embodiments, the therapy control circuit 982 controls the delivery of the one or more therapies based on whether AF is detected and verified, and may be configured to start, stop, or adjust the delivery of the therapy in the one or more therapies in response to the verified detection of AF. The storage control circuit 978 starts storing the one or more cardiac signals in response to the detection of one of the one or more types of arrhythmias. In one embodiment, the storage control circuit 978 stops storing the one or more cardiac signals when the type of arrhythmia is no longer detected. In various embodiments, the storage control circuit 978 begins storing the one or more cardiac signals in response to verified detection of AF and stops storing when AF is no longer detected or verified.

[0080] It should be understood that the above detailed description is intended to be illustrative, rather than restrictive. By reading and understanding the above description, other embodiments will be apparent to those skilled in the art. Therefore, the scope of the present invention should be determined with reference to the full scope of the equivalents given by the appended claims and these claims.

Claims

1. A system comprising: a sensing circuit configured to sense cardiac signals indicative of atrial depolarization and ventricular depolarization; as well as an atrial fibrillation (AF) detection circuit configured to detect AF using the cardiac signal, the AF detection circuit comprising: a detector configured to detect the ventricular depolarization using the cardiac signal, to measure a ventricular interval each between two consecutively detected ventricular depolarizations, and to detect the AF using the ventricular interval; and a detection enhancer comprising a respiratory sinus arrhythmia (RSA) detector configured to detect RSA using the cardiac signal, and the detection enhancer is configured to verify each detection of the AF based on whether the RSA is detected, the RSA detector comprising: a run detector configured to detect a run having successive faster heartbeats and successive slower heartbeats according to the heart signal within a time period; and a run analyzer configured to analyze the detected runs for use in an RSA profile, And in response to the presence of the RSA graph, declaring the detection of the RSA.

2. A system according to claim 1, wherein the detector is configured to calculate a measure of ventricular rate variability using the ventricular interval and to indicate a recommended detection of the AF in response to the measure of ventricular rate variability satisfying one or more criteria for the AF, and the detection enhancer is configured to indicate detection of the AF in response to indicating the recommended detection of the AF while the RSA is not detected.

3. The system of claim 1, wherein the detection enhancer is configured to negate detection of the AF when the RSA is detected.

4. The system of claim 1, wherein the detection enhancer is configured to indicate a false positive detection of the AF when the AF is detected by the detector simultaneously with the detection of the RSA.

5. A system according to any one of claims 1 to 4, wherein the run analyzer is configured to generate a histogram of the percentage of each run having a number of heartbeats plotted against the duration of the run specified by the number of heartbeats.

6. A system according to claim 5, wherein the run analyzer is configured to detect at least one of the RSA profiles including a significantly low percentage of 1-beat runs or an increase in the number of multi-beat runs as the number of beats in each of the multi-beat runs increases.

7. The system of any one of claims 1 to 4, comprising an implantable medical device comprising the sensing circuit and the AF detection circuit.

8. The system of claim 7, wherein the sensing circuit is configured to sense a ventricular electrogram.

9. The system of claim 7, wherein the sensing circuit is configured to sense a subcutaneous electrocardiogram.

10. The system of claim 7, wherein the implantable medical device comprises an implantable loop recorder.

11. The system according to any one of claims 1 to 4, further comprising: a therapeutic device configured to deliver one or more therapies; as well as Therapy control circuitry is configured to control delivery of the one or more therapies based on whether each detection of the AF is verified.

12. The system of claim 7, wherein the implantable medical device comprises a subcutaneous implantable cardioverter-defibrillator.

13. The system of claim 7, wherein the implantable medical device comprises a ventricular implantable cardioverter-defibrillator.

14. The system according to any one of claims 1 to 4, further comprising: a storage device configured to store portions of the sensed cardiac signal; as well as A storage control circuit is configured to initiate storage of a portion of the portions of the sensed cardiac signal in response to each detection of AF being verified.